Financial reports
10-Q
2024 Q2
Quarterly report
13 Feb 24
10-Q
2024 Q1
Quarterly report
14 Nov 23
ARS
2023 FY
Annual report to shareholders
30 Oct 23
10-K
2023 FY
Annual report
22 Sep 23
10-Q
2023 Q3
Quarterly report
11 May 23
10-Q
2023 Q2
Quarterly report
10 Feb 23
10-Q
2023 Q1
Quarterly report
10 Nov 22
10-K
2022 FY
Annual report
9 Sep 22
10-Q
2022 Q3
Quarterly report
11 May 22
10-Q
2022 Q2
Quarterly report
11 Feb 22
Current reports
8-K
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024
13 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
21 Nov 23
8-K
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024
14 Nov 23
8-K
Departure of Directors or Certain Officers
6 Oct 23
8-K
Departure of Directors or Certain Officers
28 Sep 23
8-K
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023
20 Sep 23
8-K
Termination of a Material Definitive Agreement
5 Sep 23
8-K
Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates
11 May 23
8-K
Other Events
11 Apr 23
8-K
Other Events
28 Mar 23
Registration and prospectus
S-1
IPO registration
2 Nov 22
D
$16.19 mm in equity / options / securities to be acquired, sold $6.65 mm, 5 investors
7 Oct 22
S-8
Registration of securities for employees
21 Apr 22
424B4
Prospectus supplement with pricing info
10 May 21
8-A12B
Registration of securities on exchange
5 May 21
S-1/A
IPO registration (amended)
5 May 21
FWP
Free writing prospectus
26 Apr 21
S-1/A
IPO registration (amended)
26 Apr 21
S-1
IPO registration
1 Apr 21
DRS/A
Draft registration statement (amended)
12 Mar 21
Other
EFFECT
Notice of effectiveness
10 Nov 22
CORRESP
Correspondence with SEC
8 Nov 22
UPLOAD
Letter from SEC
8 Nov 22
EFFECT
Notice of effectiveness
7 May 21
CERT
Certification of approval for exchange listing
7 May 21
CORRESP
Correspondence with SEC
5 May 21
CORRESP
Correspondence with SEC
5 May 21
CORRESP
Correspondence with SEC
5 May 21
UPLOAD
Letter from SEC
4 May 21
CORRESP
Correspondence with SEC
26 Apr 21
Ownership